




Overview of Gastric Cancer in the World

Valerio Sisti, Pesaro, Italy

Andrea Costanzi, Milan, Italy

Paolo Morgagni, Forlì, Italy

G.I.R.C.G. (*Italian Gastric Cancer Research Group*)



AUSTRALIA

Authors: *Thomson I.G. & Smithers B.M.*

Upper Gastrointestinal and Soft Tissue Unit
Princess Alexandra Hospital & Department of Surgery
The University of Queensland, Brisbane

Incidence:

Males: 12,7/100.000 Females: 5,8/100.000 All: 5,8/100.000

Mortality:

Males: 7,4/100.000 Females: 3,2/100.000 All: 5,1/100.000

Presence of national guidelines on gastric cancer: YES

Application of guidelines in clinical practice: NO

National Associations for research on gastric cancer: YES

ANZGOSA (Australian and New Zealand Gastric and Oesophageal Surgery Association)
AGITG (Australasian Gastrointestinal Trials Group)

National Trials ongoing: YES

- **TOPGEAR:** Trial of preoperative therapy for gastric and esophagogastric junction adenocarcinoma. A randomised phase II/II trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer.

Relevant studies published in recent 2 years: 2011-2013: 18 studies published

- Baird M, Woon Ang P, et al. The unfolded protein response is activated in Helicobacter-induced gastric carcinogenesis in a non-cell autonomous manner. *Lab Invest.* 2013;93(1):112-22.
- Tourani SS, Cabalag C, et al. Laparoscopy and peritoneal cytology: important prognostic tools to guide treatment selection in gastric adenocarcinoma. *ANZ J Surg.* 2013.
- Thomson IG, Gotley DC, et al. Treatment results of curative gastric resection from a specialist Australian unit: low volume with satisfactory outcomes. *Gastric Cancer.* 2013.
- Thiem S, Pierce TP, et al. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. *J Clin Invest.* 2013;123(2):767-81.
- Castano-Rodriguez N,. The role of TLR2, TLR4 and CD14 genetic polymorphisms in gastric carcinogenesis: a case-control study and meta-analysis. *PLoS One.* 2013;8(4):e60327



Republic of BELARUS

Authors: *Shmak A.I., Reutovich M.Yu.*

N.N. Alexandrov National Cancer Center of Belarus, Minsk

Incidence:

Males: 40,5/100.000 Females: 25,6/100.000 (Belarus Cancer Registry)

Mortality:

Males: 27,0/100.000 Females: 16,1/100.000 (Belarus Cancer Registry)

Presence of national guidelines on gastric cancer: YES

Application of guidelines in clinical practice: YES

National Associations for research on gastric cancer: NO

*There are no national associations dealing with gastric cancer research.
All relevant research is conducted by N.N. Alexandrov National Cancer Center of Belarus.*

National Trials ongoing: YES

Randomized trials are conducted at N.N. Alexandrov National Cancer Center of Belarus

- Development and implementation of a new comprehensive method of managing gastric cancer patients employing chemoradiotherapy to lower risks of loco-regional recurrences and distant metastases.

- Development of a comprehensive method treating gastric cancer patients employing Intraperitoneal Hyperthermo-Chemo-Perfusion with a view to lowering risks of implantation metastases in radically operated patients, stages IIB-IIIIC.

Relevant studies published in recent 2 years:

- Reutovich M.Yu. Intraperitoneal Hyperthermo-Chemo-Perfusion in Treating Resectable Gastric Cancer: First Experience in Belarus

Oncology News. – 2012. – Vol. 7, Issue 2. – P. 48–50.

- Reutovich M., Shmak A.I. Efficacy of hyperthermo-chemoperfusion (IHCP) in the prevention of peritoneal recurrence in patients with respectable gastric cancer

7th NCRI cancer conference (Liverpool, UK, November 6-9, 2011). P. 298-299.



BRAZIL

Authors: *Oswaldo Castro*

Brazilian Gastric Cancer Association



Incidence:
Males: 13,2/100.000 Females: 7,2/100.000
Mortality in 2010
Males: 8.633 cases Females: 13.402 Total: 22.035
Presence of national guidelines on gastric cancer: YES
Application of guidelines in clinical practice: YES
National Associations for research on gastric cancer: YES
National Associations for research on gastric cancer: Brazilian Gastric Cancer Association (http://www.abcg.org.br)
National Trials ongoing: In preparaton
Relevant studies published in recent 2 years:
<u>Zilberstein B, Malheiros C, Lourenço LG, Kassab P, Jacob CE, Weston AC, Bresciani CJ, Castro O, Gama-Rodrigues J.</u> <u>Brazilian consensus in gastric cancer: guidelines for gastric cancer in Brazil.</u> <u>Arq Bras Cir Dig. 2013 Mar;26(1):2-6.</u> <u>[Article in English, Portuguese]</u>
Source <u>Associação Brasileira de Câncer Gástrico, São Paulo, SP, Brasil.</u>



CANADA

Authors: Brar S., Mahar A., Dixon M., Helyer L., Law C., McLeod R., Wirtzfeld D., Swallow C, and Coburn N

Incidence:

Males: 9.5/100.000 Females: 4.5/100.000

Mortality:

Males: 5.7/100.000 Females: 2.8/100.000

Presence of national guidelines on gastric cancer: NO

No National guidelines; provincial guidelines do exist in several jurisdictions

Application of guidelines in clinical practice: NO (No data currently available on application of guidelines)


National Associations for research on gastric cancer: NO

National Trials ongoing: YES

1. TOPGEAR - Preoperative chemoradiotherapy vs preoperative chemotherapy for resectable cancer of stomach or gastroesophageal junction
2. INTEGRATE – Phase II Study of Regorafenib in refractory advanced esophago-gastric cancer
3. Phase II Study of Adjuvant Radiochemotherapy for Gastric Cancer
4. A Multicentre, Open-label Phase II Study of Irinotecan, Capecitabine(Xeloda), and Oxaliplatin (IXO) as First Line Treatment in Patients With Metastatic Gastric or Gastroesophageal (GEJ) Adenocarcinoma
5. A Phase 3, Multicentre, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
6. A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
7. A Study of Onartuzumab (MetMab) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)

Relevant studies published in recent 2 years: 2010-2013: 14 studies published

- Coburn N, et al: Optimal Management of Gastric Cancer: Results From an International RAND/UCLA Expert Panel. Ann Surg. 2013
- Coburn NG. Systematic Reviews - Current issues in gastric cancer management. Gastric Cancer. 2012 Sep;15 Supplemental 1:S1-167
- Munene G, et al: The quality of life trajectory of resected gastric cancer. J Surg Oncol. 2012 Mar 15;105(4):337-41
- MacLellan SJ, et al: Laparoscopic gastrectomy for patients with advanced gastric cancer produces oncologic outcomes similar to those for open resection. Surg Endosc. 2012 Jul;26(7):1813-21
- Worthley DL, et al Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut. 2012 May;61(5):774-9



CILE

Authors: *Dr. Carlos Garcia C.; Dr. Carlos Esperquel G.; Dr. Carlos Benavides C.*

Hospital San Borja-Arriarán, Universidad de Chile

Incidence:

Males: 34.1/100.000 Females: 12.8/100.000

Mortality:

Males: 29.4/100.000 Females: 11/100.000

Presence of national guidelines on gastric cancer: YES

- MINISTERIO DE SALUD. Guía Clínica CÁNCER GÁSTRICO. SANTIAGO: Minsal, 2010.
- www.minsal.cl/portal/url/.../722233c6b943cd08e04001011f011d5e.pdf

Application of guidelines in clinical practice: YES OBLIGATORY

National Associations for research on gastric cancer: YES

Sociedad de Cirujanos de Chile

National Trials ongoing: YES

Descriptive study of prospective clinical series of patients with locally advanced gastric cancer treated with perioperative chemotherapy and surgery

Relevant studies published in recent 2 years:

1. Gastroesophageal Adenocarcinoma: analysis of surgical treatment. Drs: García C., et Panamerican gastric cancer congress. Porto Alegre, Brazil Sep. 2012.
2. Prognostic value of extracapsular lymph node involvement among patients with gastric cancer. Tapia EO, et al: Rev Med Chil. 2011 Aug;139(8):992-7.
3. Completely laparoscopic versus open gastrectomy for early and advanced gastric cancer: a matched cohort study. Moisan F, et al: Surg Endosc. 2012 Mar;26(3):661-72.
4. Wnt/ β -catenin signaling enhances cyclooxygenase-2 (COX2) transcriptional activity in gastric cancer cells. Nuñez F, et al: PLoS One. 2011 Apr 6;6(4):e18562.
5. Reprimo as a potential biomarker for early detection in gastric cancer. Bernal C, et al: Clin Cancer Res. 2008 Oct 1;14(19):6264-9.




CHINA

Authors: *Jiafu Ji MD.,*

Department of Surgery

*Peking University Cancer Hospital & Institute
Beijing*

Incidence: <i>(Chinese Cancer Registry Annual Report. 2012)</i>
Males: 49.61/100.000 Females: 22.50/100.000 Both sexes: 36.21/100.000
Mortality: <i>(Chinese Cancer Registry Annual Report. 2012)</i>
Males: 34.64/100.000 Females: 16.91/100.000 Both Sexes: 25,88/100.000
Presence of national guidelines on gastric cancer: YES
Application of guidelines in clinical practice: YES
National Associations for research on gastric cancer: YES
<i>China Anti-cancer Association/ Gastric Cancer Association</i>
National Trials ongoing: YES
Indication for diagnosis or chemoprevention: - ChiCTR-TRC-10000979 A large intervention trial to prevent gastric cancer by eradication of H. pylori in Linqu. - NCT-01133951:Helicobacter Pylori Eradication to Prevent Gastric Cancer - NCT00498134:Chemoprevention of Gastric Cancer by Intervention With Helicobacter Pylori and Cyclooxygenase Pathway - NCT01642797: Confocal Laser Endomicroscopy for the Diagnosis of Gastric Intestinal Metap, Intraep Neoplasia, and Carcinoma -NCT00164892:Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer (Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial Indication for advanced gastric cancer: - NCT01450696:HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer - NCT00811447:Taxotere New Indication - Gastric Cancer Treatment Registration Trial - NCT01512745:Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer -NCT01839500:EVIDENCE: A Non-Interventional Study of Treatment and Clinical Outcomes in Chinese Patients With Gastric Cancer Indication for locally advanced gastric cancer - NCT01534546:Phase III Study to Compare Perioperative Chemot of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemot in Locally Advanced Gastric Adenocarcinoma With D2 Dissection - NCT00591045:Study of Oxaliplatin, Calcium Folate, and 5-Fluorouracil as Neoadj Chemot for Resectable Advanced Gastric Cancer - NCT01609309:Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01) - NCT00992199: R.C.Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Local Advanced Gastric Cancer (IPchemo-AGC) - NCT01558947:Peri-operative Chemotherapy With ECX or XP in the Treatment of Advanced Gastric Cancer - NCT01583361:SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer (RESONANCE) - NCT01197118:Postoperative Sequence Chemoradiotherapy Compared With Chemotherapy Alone for Advanced Gastric Cancer - NCT01364376:S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma (Focus) - NCT01665274:A Randomized Single Center Controlled Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With Capecitabine (XELOX) Versus XELOX as Post-operative Chemotherapy in Advanced Gastric Adenocarcinoma With D2 Dissection - NCT01516944:Perioperative Chemotherapy for Potentially Resectable Gastric Cancer - NCT01795027:Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemot After D2 Resection in Pts With Gastric Cancer (POTENT)
Relevant studies published in recent 2 years: <u>2011-2013: 15 studies published</u>
- Wu XJ, et al.: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination. Tumour biology 2013; 34:463 - Hu W, et. Incorporating breath holding and image guidance in the adjuvant gastric cancer radiotherapy: a dosimetric study. Rad.Oncol 2012 Li ZY, et. Neoadjuvant chemotherapy with FOLFOX: improved outcomes.....; <i>Journal of surgical oncology</i> 2012; 105:793-9 . - Chen JS, et al.: A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment.....; Gastric cancer 2012; 15:49-55 . - Yu C, et al. Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery. Journal of cancer research and clinical oncology 2012; 138:255-9



DENMARK

Authors: Lone S. Jensen, Lars Bo Svendsen,
Peter Brøndum Mortensen

DECV-group, Denmark

Incidence:
Males: 6/100.000 Females: 4/100.000
Mortality:
Males: 6,1/100.000 Females: 3,1/100.000
Presence of national guidelines on gastric cancer: YES (since 2002)
Application of guidelines in clinical practice: YES (since 2002)
National Associations for research on gastric cancer: YES
Danish Esophageal, GEJ and Gastric Cancer Group
National Trials ongoing: YES
Trials concerning factors and coherence between lymph node dissection, anastomotic insufficiency and prognosis
Relevant studies published in recent 2 years:
Jensen LS, Nielsen H, Mortensen PB, Pilegaard HK, Johnsen SP. <i>Enforcing centralization for gastric cancer in Denmark.</i> Eur J Surg Oncol (2010).
Dikken JL, van Sandick JW, Allum WH, Johansson J, Jensen LS et al. <i>Differences in outcomes of esophageal and gastric cancer surgery across Europe.</i> Br j Surg (2012)



ESTONIA

Authors: Arak A., Ojamaa K., Adamson M.

East Tallinn Central Hospital, Tallinn

Incidence:

Males: 28,7/100.000 Females: 14,9/100.000

Mortality:

All: 12,7/100.000

Presence of national guidelines on gastric cancer: NO

Diagnostic and treatment procedures for GC are based on the principles and recommendations of the NCCN, ESMO and JGC guidelines

Application of guidelines in clinical practice: YES


National Associations for research on gastric cancer: NO

National Trials ongoing:


2003: first institutional study in Estonia using normothermic intraoperative and early postoperative intraperitoneal chemotherapy after complete cytoreduction for patients with peritoneal carcinomatosis as only site of distant metastases to assess patients selection criteria.

2011: HIPEC was introduced as a part of treatment protocol for patients with high risk for peritoneal recurrence.

Relevant studies published in recent 2 years: none



Incidence of gastric cancer in Estonia by extent of spread at the time of diagnosis (Estonian Cancer Registry, 2008)



FINLAND

Authors:

Kokkola A, Puolakkainen P

Incidence:
Males: 6.8/100.000 Females: 3.9/100.000
Mortality:
Males: 5.0/100.000 Females: 2.7/100.000
Presence of national guidelines on gastric cancer: NO
Application of guidelines in clinical practice:
<ul style="list-style-type: none">• T2-4 cancer: perioperative EOX and D2 gastrectomy• T1 cancer operation only
National Associations for research on gastric cancer: NO
National Trials ongoing: NO
Relevant studies published in recent 2 years: NONE



FRANCE

Authors:

G Piessen, M Messenger, C Gronnier, WB Robb, C Mariette

Department of Digestive and Oncological Surgery,
Lille University Hospital

Incidence:

Males: 13,8/100.000 Females: 6,76/100.000 All: 10,21/100.000

Mortality:

Males: 9,18/100.000 Females: 4.98/100.000 All: 7.02/100.000

Presence of national guidelines on gastric cancer: YES (<http://www.tncd.org/>)

Application of guidelines in clinical practice: YES

National Associations for research on gastric cancer: YES

FREGAT : FRENch Eso-GAstric Tumours working group

FRENCH: French Federation of Surgical Research

National Trials ongoing: YES

- PRODIGE 19 - FFCD 1103 - ADCI 002: Phase II/III randomised multicentre trial comparing primary surgery to primary chemotherapy in resectable signet ring cell gastric adenocarcinomas (Principal investigators: Dr G Piessen, Pr C Mariette, Pr A Adenis)
- GASTRICHIP Trial: D2 Resection and HIPEC (Hyperthermic intraperitoneal chemoperfusion) in locally advanced gastric carcinoma. A randomized and multicentric phase III study (Principal Investigator: Pr O Glehen)
- FFCD0901– FRENCH trial: Trial Evaluating the Efficacy and Tolerance of Perioperative Chemotherapy With 5FU-Cisplatin-Cetuximab in Adenocarcinomas of the Stomach and Gastroesophageal Junction. Phase II Single Arm, Multicenter- Intergroup trial (Principal investigators: Pr C Mariette, Pr O Bouché)
- IIPOP Trial: A randomized multicentric trial using Perioperative Intraperitoneal Immunotherapy after complete cytoreductive surgery in patients with gastric cancer presenting a limited Peritoneal Carcinomatosis (Principal Investigator: Pr D Elias)
- 09.54 CLI International phase III trial –Immunonutrition to improve the quality of life of upper gastrointestinal cancer patients undergoing neoadjuvant treatment prior to surgery (Principal investigator: Pr C Mariette)
- FREGAT: French National oeso-gastric cancer database (Principal investigator: Pr C Mariette, Pr A Adenis)
- Phase II Multicenter Study in the Preoperative Treatment of Gastric Adenocarcinoma Consisting of Chemotherapy Using Docetaxel-cisplatin-5FU + Lenograstim Followed by Chemoradiation Based 5FU and Oxaliplatin (Principal Investigator : Dr L Mineur)

Relevant studies published in recent 2 years: 2011-2013 9 studies published

- Piessen G, et. Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas -- PRODIGE 19 -- FFCD1103 -- ADCI002. *BMC Cancer*. 2013;13(1):281.
- Cotte E, et al. Lack of prognostic significance of conventional peritoneal cytology in colorectal and gastric cancers: Results of EVOCAPE 2 multicentre prospective study. *Eur J Surg Oncol*. 2013;39:707-14.
- Piessen G, et al. Gastric signet ring cell carcinoma: how to investigate its impact on survival. *J Clin Oncol*. 2013;31:2059-60.
- Robb WB, et al. Predictive Factors of Postoperative Mortality After Junctional and Gastric Adenocarcinoma Resection. *JAMASurg*. 2013
- Honoré C, et al. Risk factors of peritoneal recurrence in eso-gastric signet ring cell adenocarcinoma: results of a multicentre retrospective study. *Eur J Surg Oncol*. 2013;39:235-41.



GERMANY

Authors:

*S.P. Mönig, A.H. Hölscher, E. Bollschweiler,
H.J. Meyer*

Incidence:

Males: 16.8/100.000 Females: 8.6/100.000 (2008)

Mortality:

Males: 10.5/100.000 Females: 5.6/100.000 (2008)

Presence of national guidelines on gastric cancer: YES

German S3-Guideline (Moehler M. et al., Z Gastroenterol 2011; 49, 461-531)

Application of guidelines in clinical practice: YES

National Associations for research on gastric cancer: YES


DGAV: CAOGI, DKG/AIO

National Trials ongoing: YES

- AIO-YMO-0111/STO: Randomized controlled trial of induction therapy followed by De-escalation phase with S-1 in metastatic gastric cancer
- AIO/CAO-STO-0801: An Open label Randomized Phase II trial of Panitumumab in combination with Epirubicin, Cisplatin and Capecitabine (ECX) versus ECX chemotherapy alone in Subjects with Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction (NEOPEXC)
- AIO-STO-0210: Multizentrische, randomisierte Phase II/III Studie mit 5-FU, Leucovorin, Oxaliplatin und Docetaxel (FLOT) versus Epirubicin, Cisplatin und 5-FU (ECF) bei Patienten mit lokal fortgeschrittenem, resektablem Adenokarzinom des ösophagogastralen Überganges und des Magens (FLOT4)
- AIO-STO-0310 Multicenter, explorative phase II study of perioperative 5-FU, leucovorin, docetaxel, and oxaliplatin (FLOT) in combination with trastuzumab in patients with HER2 positive, locally advanced, resectable adenocarcinoma of the gastroesophageal junction or stomach (HerFLOT)
- AIO-STO-0309 – An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced or metastatic esophageal squamous cell cancer (ESCC) – POWER-Studie
- AIO-STO-0510: Pazopanib mit 5-FU, Leucovorin und Oxaliplatin als Erstlinienbehandlung beim fortgeschrittenen Magenkarzinom; eine Phase II Studie – Die PaFLO-Studie.
- AIO-STO-0312: Multizentrische, Phase II Studie mit Cabazitaxel als Zweitlinientherapie bei Patienten mit fortgeschrittenem oder metastasiertem Adenokarzinom des ösophagogastralen Überganges und des Magens
- AIO-STO-0110: Explorative trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinoma prior to gastrectomy
- AIO-STO-0111: Randomized, Double-blind, Multi-center Phase III Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma Who Have Progressed After Therapy With a Fluoropyrimidine-containing Regime

Relevant studies published in recent 2 years

- Al-Batran et al. *FLOT65+*. Eur J Cancer 2013; 49, 835-842
- Lordick et al. *EXPAND*, Lancet Oncol 2013; 14, 490-499
- Kripp et al. *Quality of Life of older adult patients*. Gastric Cancer 2013
- Thuss-Patience et al. *Survival advantage for irinotecan vs. best supportive care*. Eur J Cancer 2011; 47: 2306-2314



JAPAN

Authors: M.Terashima and M. Sasako

Incidence:

Males: 84,82/100.000 Females: 38,628/100.000

Mortality:

Males: 32,785/100.000 Females: 17,045/100.000

Presence of national guidelines on gastric cancer: YES

Gastric Cancer (2011) 14:97–100 DOI 10.1007/s10120-011-0040-6

Application of guidelines in clinical practice: YES

National Associations for research on gastric cancer: YES

Japanese Gastric Cancer Association

National Trials ongoing: YES

- Early cancer: JCOG0912, JCOG1010
- Locally advanced: JCOG0501, JCOG1001, JCOG1002, JCOG1104, JACCROGC-07
- Metastatic: JCOG0705, JCOG1013, JCOG1108, JACCROGC-06, JFMC43-1003, Phoenix-gc, HERBIS

Relevant studies published in recent 2 years

- Nashimot A, et al: *Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry.* Gastric Cancer. 2013, 16:1-27.
- Iwasaki Y, et al: *Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210).* J Surg Oncol. 2013, 107:741-5.
- Sasako M, et al: *Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.* J Clin Oncol. 2011, 29(33):4387-93.
- Miyashiro I, et al: *Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2.* Gastric Cancer. 2011, 14:212-8



HONG KONG

Authors:

Enders Kwok-wai Ng

Surgery, Chinese University of Hong Kong

Incidence:

Males: 20.4/100.000 Females: 11.6/100.000

Mortality:

Males: 12.8/100.000 Females: 7.1/100.000

Presence of national guidelines on gastric cancer:NO

Application of guidelines in clinical practice: NO

National Associations for research on gastric cancer: NO

National Trials ongoing: Not Available

Relevant studies published in recent 2 years:

- 1: Chiu PW, et al.: Recognition of goblet cells upon endocytoscopy indicates the presence of gastric intestinal metaplasia. *Dig Endosc.* 2013 Mar 31. doi: 10.1111/den.12050
- 2: Cheng AS, et al: Helicobacter pylori causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis. *Gastroenterology.* 2013 Jan;144(1):122-133.e9
- 3: Sung JJ, et al.; Asia Pacific GI Oncology Summit Group. Digestive cancer management in Asia: position statements: a report on GI Oncology Summit in 2011. *J Gastroenterol Hepatol.* 2012 Sep; 27(9):1417-22.
- 4: Du W, et al: ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer. *Oncogene.* 2012 Aug 20
- 5: Chiu PW, et al: Endoscopic submucosal dissection (ESD) compared with gastrectomy for treatment of early gastric neoplasia: a retrospective cohort study. *Surg Endosc.* 2012 Dec;26(12): 3584-91.



INDIA

Authors: Chandramohan SM, Kannan D, Kanagavel M, Swaminathan R, Sandeep R, Selvarathinam P, Rajamahendran R
 Department of Surgical Gastroenterology
 Center of Excellence for Upper GI Surgery
 Madras Medical College, Chennai

Incidence:

Males: 11.8/100.000 Females: 5,9/100.000

Mortality:

Males: 3.9/100.000 Females: 2.1/100.000

Presence of national guidelines on gastric cancer: YES

1. TATA MEMORIAL HOSPITAL Guidelines
2. ESO INDIA Guidelines (march 2013, analysis in progress and to be published)

Application of guidelines in clinical practice: YES (in selected center)

National Associations for research on gastric cancer: YES

Indian council of Medical Research; Association of Surgeons of india
 Indian Association of Surgical Gastroenterology; Indian Society of Gastroenterology;
 Indian Association of Surgical Oncology; ESOINDIA

National Trials ongoing: YES

- Uncut roux-en-y gastrojejunostomy VS standard roux-en-y gastrojejunostomy following partial gastrectomy or palliative bypass
- EGF110656 : A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
- Phase 1b/2 clinical trial: Safety and Efficacy of First-line Treatment With ECX Plus drug AMG 102.
- IMC-1121B and best supportive care (BSC) versus Placebo and BSC in patients with metastatic gastric or EGJ adenocarcinoma
- Phase IV study of trastuzumab in combination with the standard chemotherapy as first-line therapy
- A Study to determine the Factors Affecting the Survival in Patients with Gastric cancer Undergoing Surgery
- Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients (SHINE)
- To assess the safety and tolerability of a single oral dose of the Capecitabine test and reference formulations.
- Trial comparing surgery first or chemotherapy first in stomach cancer
- Incidence of Her 2 testing on pathology of patients with gastric cancer
- Short term and Long term outcomes of Stapler vs Hand sewn Oesophagojejunal anastomosis after Total gastrectomy
- Analysis of Three Gene signatures in Gastric cancer patients
- Analysis of Three Gene signatures in Gastric cancer patients
- Endoscopic Submucosal Dissection (ESD)- Master Slave Robotic System - Human Study
- OS of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT
- OS of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT
- Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Patients With Gastric Cancer and Adenocarcinoma
- A Comparison Between D1 and D2 Lymphadenectomy in Gastric Cancer : A Prospective Randomized Controlled Trial

Relevant studies published in recent 2 years:

- Kakroo SM et al: *Staging Laparoscopy in Carcinoma of Stomach: A Comparison with CECT Staging*; Int J Surg Oncol. 2013; 2013
- Gopala Krishnappa BR et al: *Trends in oesophagus and Stomach cancer incidence in Bangalore, India*; Gulf J Oncolog. 2013 Jan;1(13)
- Siddavaram Nagini: *Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention*; World J Gastrointest Oncol. 2012 July 15; 4(7): 156–169
- Ashish Saxena et al: *Analysis of p53, K-ras gene mutation & Helicobacter pylori infection in patients with gastric cancer & peptic ulcer disease at a tertiary care hospital in north India*; Indian J Med Res. 2012 October; 136(4): 664–670
- Rajesh P et al: *Epidemiological review of gastric cancer in India*; Indian J Med Paediatr Oncol. 2011 Jan-Mar; 32(1): 3–11
- Ramakrishnan A et al: *Prognostic factors in patients with node-negative gastric cancer: an Indian experience*; W J Surg Oncol. 2011



United Kingdom

Author:

*Prof. A. Nisar, Consultant Upper G.I. Surgeon,
Maidstone and Tunbridge Wells NHS trust, UK*

Incidence:

Males: 10/100.000 Females: 4.8/100.000

Mortality:

Males: 6.6 /100.000 Females: 3.1/100.000

Presence of national guidelines on gastric cancer: YES

Guidelines for the management of oesophageal and gastric cancer, Gut 2011, AUGIS, BSG, BASO

Application of guidelines in clinical practice: YES

National Associations for research on gastric cancer: NO (only for audit of data)

National Oesophago-Gastric Cancer Audit, supported by the British Society of Gastroenterology, the Association of Upper Gastrointestinal Surgeons (AUGIS) and the Royal College of Surgeons of England Clinical Effectiveness Unit

National Trials ongoing: YES

72 studies found for gastric cancer on www.clinicaltrials.gov

Relevant studies published in recent 2 years:

National outcomes and uptake of laparoscopic gastrectomy for cancer in England. Mamidanna R, Almoudaris AM, Bottle A, Aylin P, Faiz O, Hanna GB. Surg Endosc. 2013 Apr 24.

Real Time Cancer Prediction Based on Objective Tissue Compliance Measurement in Endoscopic Surgery. Fakhry M, Bello F, Hanna GB. Ann Surg. 2013 Apr 1.

Impact of route to diagnosis on treatment intent and 1-year survival in patients diagnosed with oesophagogastric cancer in England: a prospective cohort study. Palser TR, Cromwell DA, Hardwick RH, Riley SA, Greenaway K, van der Meulen JH; National Oesophago-Gastric Cancer Audit. BMJ Open. 2013 Feb 13;3(2).

Long-Term Survival After Gastrectomy for Cancer in Randomized, Controlled Oncological Trials: Comparison between West and East. Markar SR, Karthikesalingam A, Jackson D, Hanna GB. Ann Surg Oncol. 2013 Jul;20(7):2328-38.

Gastric cancer in 2012: Defining treatment standards and novel insights into disease biology. Smyth EC, Cunningham D. Nat Rev Clin Oncol. 2013 Feb;10(2):73-4



ISRAEL

Authors:

A. Halevy

Incidence:

Jewish: Males: 12,7/100.000 Females: 5,8/100.000

Arabs:

Mortality:

Jewish: Males: 7,4/100.000 Females: 3,2/100.000

Arabs:

Presence of national guidelines on gastric cancer: YES

Application of guidelines in clinical practice: NO

National Associations for research on gastric cancer: YES

ANZGOSA (Australian and New Zealand Gastric and Oesophageal Surgery Association)
AGITG (Australasian Gastrointestinal Trials Group)

National Trials ongoing: YES

- **TOPGEAR:** Trial of preoperative therapy for gastric and esophagogastric junction adenocarcinoma. A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer.

Relevant studies published in recent 2 years: 2011-2013: 18 studies published

- Baird M, Woon Ang P, Clark I, Bishop D, Oshima M, Cook MC, et al. The unfolded protein response is activated in Helicobacter-induced gastric carcinogenesis in a non-cell autonomous manner. *Lab Invest.* 2013;93(1):112-22.
- Tourani SS, Cabalag C, Link E, Chan ST, Duong CP. Laparoscopy and peritoneal cytology: important prognostic tools to guide treatment selection in gastric adenocarcinoma. *ANZ J Surg.* 2013.
- Thomson IG, Gotley DC, Barbour AP, Martin I, Jayasuria N, Thomas J, et al. Treatment results of curative gastric resection from a specialist Australian unit: low volume with satisfactory outcomes. *Gastric Cancer.* 2013.
- Thiem S, Pierce TP, Palmieri M, Putoczki TL, Buchert M, Preaudet A, et al. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. *J Clin Invest.* 2013;123(2):767-81.
- Castano-Rodriguez N, Kaakoush NO, Goh KL, Fock KM, Mitchell HM. The role of TLR2, TLR4 and CD14 genetic polymorphisms in gastric carcinogenesis: a case-control study and meta-analysis. *PLoS One.* 2013;8(4):e60327



ITALY

Authors:

G.I.R.C.G. (Italian Gastric Cancer Research Group)

Incidence:

Males: 16.5/100.000 Females: 8.9/100.000

Mortality:

Males: 12.0/100.000 Females: 6.1/100.000

Presence of national guidelines on gastric cancer: NO

Application of guidelines in clinical practice: YES in selected center

National Associations for research on gastric cancer: YES

GIRCG: Italian Gastric Cancer Research Group

IGCSG: Italian Gastric Cancer Study Group

National Trials ongoing: YES

54 studies found for gastric cancer (www.clinicaltrials.gov)

Relevant studies published in recent 2 years:

- Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. **Corso G et al, J Clin Oncol 2013**
- Prognostic value of the 7th AJCC/UICC TNM classification of noncardia gastric cancer: analysis of a large series from specialized Western centers. **Marrelli D et al. (GIRCG), Ann Surg. 2012**
- Tumor site and perigastric nodal status are the most important predictors of para-aortic nodal involvement in advanced gastric cancer. **de Manzoni G et al (GIRCG), Ann Surg Oncol. 2011**
- Validation of the new AJCC TNM staging system for gastric cancer in a large cohort of patients (n = 2,155): focus on the T category. **Marchet A et al (GIRCG), Eur J Surg Oncol. 2011**
- Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. **Bozzetti C et al Br J cancer 2011**
- A multicentric Western analysis of prognostic factors in advanced, node-negative gastric cancer patients. **Baiocchi GL et al (GIRCG), Ann Surg. 2010**
- Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. **De Giuli M et al, Br J Surg 2010**



SOUTH KOREA

Authors:

*HK YANG, HH Kim,
HJ LEE, SH KONG, YS SUH*

Incidence: *Crude incidence rate in 2010*

Males: 80.8/100.000 Females: 39.8/100.000

Of all cancers in 2010, 19.6% (male) and 10.0% (female)

Mortality: *Crude mortality rate in 2011*

Males: 25.2/100.000 Females: 13.6/100.000

Of all cancers in 2011, 14.1% (male) and 12.7% (female)

Presence of national guidelines on gastric cancer: YES

Korean Clinical Practice Guideline for gastric cancer

Application of guidelines in clinical practice: YES

National Associations for research on gastric cancer: YES

The Korean Gastric Cancer Association; Korean Academy of Medical Sciences

National Trials ongoing: YES

- RCT comparing adjuvant capecitabine and oxaliplatin vs. observation for gastric cancer after D2 gastrectomy (CLASSIC)
- RCT comparing laparoscopic versus open gastrectomy for early gastric cancer (KLASS-01)
- RCT comparing laparoscopic gastrectomy with D2 dissection vs. open surgery for locally advanced gastric cancer (KLASS-02)
- Multi-national phase II trial of laparoscopic total gastrectomy for stage I gastric cancer (KLASS-03)
- RCT comparing reductive gastrectomy plus chemotherapy vs. chemotherapy alone for stage IV gastric cancer (REGATTA)
- RCT comparing trastuzumab with chemotherapy vs. chemotherapy alone for HER2-positive advanced gastric cancer (ToGA)
- Feasibility study of laparoscopy-assisted D2 distal gastrectomy to treat advanced gastric cancer (COACT1001)
- Multi-institutional study on the assessment of robotic surgery for gastric cancer
- Multi-national phase II trial of neoadjuvant imatinib for large gastric GIST

Relevant studies published in recent 2 years:

- 1.Bang YJ, et al. CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. *Lancet* 2012 Jan 28;379(9813):315-21.
- 2.Han DS, et al. Nomogram predicting long-term survival after D2 gastrectomy for gastric cancer. *J Clin Oncol* 2012 Nov; 30(31):3834-40.
- 3.Kim HH, et al.. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial). *Ann Surg* 2010 Mar;251(3):417-20.
- 4.Ahn HS, et al.. Evaluation of the seventh American Joint Committee on Cancer/International Union Against Cancer Classification of gastric adenocarcinoma in comparison with the sixth classification. *Cancer* 2010 Dec;116(24):5592-8.
- 5.Song J, et al Korean Laparoscopic Gastrointestinal Surgery Study (KLASS) Group. Recurrence following laparoscopy-assisted gastrectomy for gastric cancer: a multicenter retrospective analysis of 1,417 patients. *Ann Surg Oncol.* 2010 Jul; 17(7):1777-86.



LATVIA

Authors: *M. Leja, A. Sīviņš, G. Ancāns, R. Škapars, J. Misiņš, G. Moisejevs, I. Upmace, D. Rudzīte, J. Eglītis, V. Krūmiņš, V. Boka, A. Linē*

Incidence:
Males: 20.3/100.000 Females: 9.0/100.000 All: 13.3/100.000
Mortality:
Males: 16.9/100.000 Females: 7.1/100.000 All: 10.7/100.000
Presence of national guidelines on gastric cancer: NO
Application of guidelines in clinical practice: NO
National Associations for research on gastric cancer: YES
Latvian Helicobacter and Gastric Cancer Study Group
National Trials ongoing: YES
<ul style="list-style-type: none"> • Biomarker studies (cancer autoantibodies, volatile markers, pepsinogens) • Prevention studies, • <i>H. pylori</i>-related studies, • Surgery outcome studies
Relevant studies published in recent 2 years:
<p>- Zayakin P et al: Tumor-associated autoantibody signature for the early detection of gastric cancer. <i>Int. J. Cancer</i>. 2013 Jan 1;132(1):137-47.</p> <p>- Xu ZQ et al: A nanomaterial-based breath test for distinguishing gastric cancer from benign gastric conditions. <i>Br J Cancer</i>. 2013 Mar 5;108(4):941-50.</p> <p>- Leja M et al: Breath Testing: the Future for Digestive Cancer Detection. <i>Expert Rev. Gastroenterol. Hepatol</i>. 2013. In Press</p> <p>- Leja M et al: Markers for gastric cancer premalignant lesions: where do we go? <i>Dig Dis</i>. 2012;30(3) 268-76.</p> <p>- Vanags A et al: The first evidence of hereditary and familial gastric cancer in Latvia: implications for prevention. <i>Medicina (Kaunas)</i>. 2012;48(6):317-23</p>



LITHUANIA

Authors: Juozas Kupcinskas, Laimas Jonaitis, Audrius Ivanauskas, Gediminas Kiudelis, Limas Kupcinskas.

Lithuanian University of Health Sciences,
Department of Gastroenterology, Kaunas

Incidence:
Males: 32.8/100.000 Females: 21.7/100.000
Mortality:
Males: 25.9/100.000 Females: 15.8/100.000
Presence of national guidelines on gastric cancer: YES
Application of guidelines in clinical practice: YES
National Associations for research on gastric cancer: YES
Lithuanian Society of Gastroenterology
National Trials ongoing: NONE
Relevant studies published in recent 2 years:
<ul style="list-style-type: none"> • Kupcinskas L, et al: <i>Evolution of Helicobacter pylori susceptibility to antibiotics during a 10-year period in Lithuania.</i> APMIS. 2013 May. • Link A, et al: <i>Macro-role of microRNA in gastric cancer.</i> Dig Dis. 2012;30(3):255-67. Review. • Kupcinskas J, et al: <i>Lack of association between gene polymorphisms of Angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians.</i> BMC Med Genet. 2011 Aug 24;12:112. • Leja M, et al: <i>Interobserver variation in assessment of gastric premalignant lesions: higher agreement for intestinal metaplasia than for atrophy.</i> Eur J Gastroenterol Hepatol. 2013 Jun;25(6): 694-699. • Agréus L, et al: <i>Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers.</i> Scand J Gastroenterol. 2012 Feb;47(2):136-47 Review. • Sudraba A, et al: <i>Performance of routine Helicobacter pylori tests in patients with atrophic gastritis.</i> J Gastrointestin Liver Dis. 2011 Dec;20(4):349-54.




MONGOLIA

Authors:

Enkhamgalan T

Incidence:
Males: 45.5/100.000 Females: 21.1/100.000
Mortality:
Males: 37.8/100.000 Females: 18.1/100.000
Presence of national guidelines on gastric cancer: YES
Application of guidelines in clinical practice: YES
National Associations for research on gastric cancer: NO
National Trials ongoing:NO
Relevant studies published in recent 2 years:



IGCC
10th INTERNATIONAL GASTRIC CANCER CONGRESS
2013 Verona
June 19 - 22

NORWAY

Authors:

A.Viste

Incidence:

Males: 7/100.000 Females: 4/100.000

Mortality:

Males: 9.0/100.000 Females: 4.2/100.000

Presence of national guidelines on gastric cancer: YES

Application of guidelines in clinical practice: YES

National Associations for research on gastric cancer: YES

Norwegian Gastrointestinal Cancer Group, branch Oesophagus and Stomach


National Trials ongoing: NO

Relevant studies published in recent 2 years:

T. Hølmebakk, G. Frykholm and A. Viste, on behalf of the Norwegian Gastrointestinal Cancer Group (NGICG)

Introducing national guidelines on perioperative chemotherapy for gastric cancer in Norway: A retrospective audit

Eur J Surg Oncol 2010;36:610-616.



NEW ZEALAND

Authors:

Parry Guilford

Incidence:

Males: 8.7/100.000 Females: 3.8/100.000

Mortality:

Males: 5.9/100.000 Females: 3,1/100.000

Presence of national guidelines on gastric cancer: NO

Application of guidelines in clinical practice: NO

National Associations for research on gastric cancer: YES

New Zealand Inherited Gastric Cancer Group

National Trials ongoing: NO

Relevant studies published in recent 2 years:

Familial Gastric Cancer.

Chapter: Molecular mechanisms of hereditary diffuse gastric cancer initiation and progression.

Guilford, P and Humar, B. 2013 Springer, Italy.



The NETHERLANDS

Authors: *J Stiekema, A Trip, EPM Jansen, A Cats, H Boot, M Verheij, JW van Sandick*

Incidence:

Males: 11/100.000 Females: 7/100.000

Mortality:

Males: 10/100.000 Females: 7/100.000

Presence of national guidelines on gastric cancer: YES

<http://www.oncoline.nl/maagcarcinoom>

Application of guidelines in clinical practice: YES

National Associations for research on gastric cancer: YES

Dutch Gastric Cancer Group (<http://www.dgcg.nl/>)

Dutch Upper GI Cancer Audit (<http://duca.clinicalaudit.nl/>)




National Trials ongoing: YES

- CRITICS (locally advanced M0 disease): neoadjuvant CTx + surgery (D1.5 dissection) + CTx versus CRT
- NARCIS (Locally irresectable M0-disease): neoadjuvant CRT + surgery if feasible
- B-DOCT (Phase II, irresectable and/or M+ disease): Bevacuzimab/Docetaxel/Oxaliplatin/Capecitabine

Relevant studies published in recent 2 years

- Dikken JL et al. Differences in outcomes of oesophageal and gastric cancer surgery across Europe. *Br J Surg.* 2013;100:83-94
- Dikken JL et al. The New American Joint Committee on Cancer/International Union Against Cancer staging system for adenocarcinoma of the stomach: increased complexity without clear improvement in predictive accuracy. *Ann Surg Oncol.* 2012;19:2443-51.
- Dikken JL et al. Effect of hospital volume on postoperative mortality and survival after oesophageal and gastric cancer surgery in the Netherlands between 1989 and 2009. *Eur J Cancer.* 2012 May;48:1004-13
- Dassen AE et al. Changes in treatment patterns and their influence on long-term survival in patients with stages I-III gastric cancer in The Netherlands. *Int J Cancer.* 2013 *ePub ahead of print*
- Majewski IJ et al. An α -E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. *J Pathol.* 2013;229:621-9
- Kluijdt I et al. Dutch Working Group on Hereditary Gastric Cancer. CDH1-related hereditary diffuse gastric cancer syndrome: clinical variations and implications for counseling. *Int J Cancer.* 2012;131:367-76
- Stiekema J et al. Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach? *Eur J Surg Oncol.* 2013;39: 686-693
- Lemmens VE et al. Lymph node examination among patients with gastric cancer: variation between departments of pathology and prognostic impact of lymph node ratio. *Eur J Surg Oncol.* 2011;37:488-96.



OMAN

Authors: Raad Almehti, (FRCS, FRACS)

THE ROYAL HOSPITAL, Muscat

Incidence:

Males: 12/100.000 Females: 6/100.000

Mortality:

Absence of National mortality data base.

One study showed a 5-year overall survival rate of 16.7% . Two thirds of this were for Advanced disease

Presence of national guidelines on gastric cancer: NO

This is still in evolution. Two National meetings (last in March 2012) were held to put the frame work for the country's direction in this field.

Application of guidelines in clinical practice: YES

Until we adopt a National guideline, we still pursue the best practice from International reference resources including the **European (ESMO), Japanese (JGCA) and North American (NCCN)-** guidelines

National Associations for research on gastric cancer: NO

The two major centres with a comprehensive National Oncology platform are *The Royal Hospital* and the *Sultan Qaboos Univeristy Hospital* – both in Muscat, the capital, and both being the biggest referral teaching centres in the country.

From here most of the research emanates.

National Trials ongoing: NO

At this stage, only pertinent hospital-based research is present.

National collective data comes for epidemiological studies provided by the National Cancer Registry of Oman

Relevant studies published in recent 2 years:

H. AlMahrouqi: Incidence of Stomach Cancer in Oman and the Other Gulf Cooperation Council Countries; Oman Med Journal (2011) ,26, 4

R. AlMehti: Surgical Management of Gastric Cancer in Oman – Poster - - Asia Pacific Gastric Cancer Congress- Singapore- July 2012



POLAND

Authors: *Dawid Murawa*

Incidence:

Males: 3399 in 2010 Females: 1877 in 2010

Mortality:

Males: 3486 in 2010 Females: 1878 in 2010

Presence of national guidelines on gastric cancer: YES

Application of guidelines in clinical practice: YES

National Associations for research on gastric cancer: YES


Polish Gastric Cancer Study Group since 1977 (nine University Clinics participate)

Beside some aspects of research in gastric cancer are continue by Polish Society of Surgical Oncology (PTCHO), Polish Society of Clinical Oncology (PTOK), Polish Association of Surgery (TCHP)

National Trials ongoing: NO


Relevant studies published in recent 2 years:

- Kulig P et al: *Non-curative gastrectomy for metastatic gastric cancer: rationale and long-term outcome in multicenter settings.* Eur J Surg Oncol. 2012 Jun;38(6):490-6
- Szczepanik AM et al: *IL-6 serum levels predict postoperative morbidity in gastric cancer patients* Gastric Cancer. 2011 Aug;14(3):266-73
- Kuilg J et al: *Implications of overweight in gastric cancer: A multicenter study in a Western patient population;* Eur J Surg Oncol. 2010 Oct;36(10):969-76
- Sierzega M et al: *Impact of anastomotic leakage on long-term survival after total gastrectomy for carcinoma of the stomach;* Br J Surg. 2010 Jul;97(7):1035-42
- Kulig J et al: *Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial;* Oncology. 2010;78(1):54-61



Portugal

Incidence:
Males: 26.7/100.000 Females: 12.8/100.000
Mortality:
Males: 19.5 /100.000 Females: 8.9/100.000
Presence of national guidelines on gastric cancer: N.A.
National Associations for research on gastric cancer: N.A.
National Trials ongoing: YES
13 studies found for gastric cancer on www.clinicaltrials.gov
Relevant studies published in recent 2 years:
E-cadherin and adherens-junctions stability in gastric carcinoma: functional implications of glycosyltransferases involving N-glycan branching biosynthesis, N-acetylglucosaminyltransferases III and V. Pinho SS, Figueiredo J, Taniguchi N, Reis CA. <i>Biochim Biophys Acta</i> . 2013
Three decades of clinical-pathological trends in gastric cancer: Prospective data from a Portuguese hospital. Faria GR, Pinto-de-Sousa J, Preto JR, Sousa HS, Barbosa JA, Costa-Maia J. <i>Int J Surg</i> . 2013;11(6):472-6
Prediagnosis lifestyle exposures and survival of gastric cancer patients: a cohort study from Portugal. Ferronha I, Castro C, Carreira H, Bento MJ, Carvalho I, Peleteiro B, Lunet N. <i>Br J Cancer</i> . 2012 Jul 24;107(3):537-43
The importance of E-cadherin binding partners to evaluate the pathogenicity of E-cadherin missense mutations associated to HDGC. Figueiredo J, Söderberg O, Simões-Correia J, Grannas K, Suriano G, Seruca R. <i>Eur J Hum Genet</i> . 2013 Mar;21(3):301-9
Transcription initiation arising from E-cadherin/CDH1 intron2: a novel protein isoform that increases gastric cancer cell invasion and angiogenesis. Pinheiro H, Carvalho J, Seruca R, Oliveira C. <i>Hum Mol Genet</i> . 2012 Oct 1;21(19):4253-69
Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSg), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Dinis-Ribeiro M, Areia M, Carneiro F, Kuipers EJ; European Society of Gastrointestinal Endoscopy; European Helicobacter Study Group; European Society of Pathology; Sociedade Portuguesa de Endoscopia Digestiva. <i>Endoscopy</i> . 2012 Jan;44(1):74-94



CZECH REPUBLIC

Authors:

Hoskovec D., Krška Z.

Incidence:
Males: 11.27/100.000 Females: 5.23/100.000
Mortality:
Males: 9.06/100.000 Females: 4.16/100.000
Presence of national guidelines on gastric cancer: YES
Application of guidelines in clinical practice: YES (especially in oncological treatment)
National Associations for research on gastric cancer: NO
National Trials ongoing: YES
Neoral et al: Sentinel lymph nodes in gastric cancer (single centre)
Relevant studies published in recent 2 years:
- Simsa et al: <i>Lymph node micrometastases in gastric cancer: Final results of the Czech multicentre study</i> ; European Surgery - Acta Chirurgica Austriaca 44 (6) , pp. 388-393
- Costamagna et al: <i>Treatment of malignant gastroduodenal obstruction with a nitinol self-expanding metal stent: An international prospective multicentre registry (collaboration – Spicak)</i> ; Digestive and Liver Disease Volume 44, Issue 1, January 2012.
- Foretova et al: <i>Genetic testing and prevention of hereditary cancer at the MMCI - Over 10 years of experience</i> ; Klinicka Onkologie Volume 23, Issue 6, 2010, Pages 388-400
- Hoskovec et al: <i>Levels of CEA and Ca 19 - 9 in the sera and peritoneal cavity in patients with gastric and pancreatic cancers</i> ; Acta Cirurgica Brasileira, Volume 27, Issue 6, June 2012, Pages 410-416



Russia

Incidence:
Males: 35.8/100.000 Females: 15.6/100.000
Mortality:
Males: 30.6 /100.000 Females: 12.9/100.000
Presence of national guidelines on gastric cancer: N.A.
National Associations for research on gastric cancer: N.A.
National Trials ongoing: YES
25 studies found for gastric cancer on www.clinicaltrials.gov
Relevant studies published in recent 2 years:
Detection and Genotyping of Helicobacter pylori Gene vacA in Children with Gastroduodenal Diseases and in Adults with Gastric Cancer in Vladivostok. Stenkova AM, Lyalikova UV, Fayzullina NM, Sklyaruk NE, Rasskazov VA, Miroshnichenko VA, Isaeva MP. Bull Exp Biol Med. 2013 Apr;155(1):85-8.
Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer. Moiseyenko VM, Volkov NM, Suspistin EN, Yanus GA, Iyevleva AG, Kuligina ESh, Togo AV, Kornilov AV, Ivantsov AO, Imyanitov EN. Med Oncol. 2013 Jun;30(2):545
Helicobacter pylori Infection, Intestinal Metaplasia, and Gastric Cancer Risk in Eastern Siberia. Tsukanov VV, Butorin NN, Maady AS, Shtygasheva OV, Amelchugova OS, Tonkikh JL, Fassan M, Rugge M. Helicobacter. 2011 Apr;16(2):107-12
A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Kanagavel D, Pokataev IA, Fedyanin MY, Tryakin AA, Bazin IS, Narimanov MN, Yakovleva ES, Garin AM, Tjulandin SA. Ann Oncol. 2010 Sep;21(9):1779-85



SINGAPORE

Authors:

Jimmy So, P Tan, WP Yong, Y Ito, KG Yeoh.

Incidence:

Males: 12.1/100.000 Females: 7.2/100.000

Mortality:

Males: 8.2/100.000 Females: 4.4/100.000

Singapore Cancer Registry Interim Annual Registry Report Trends in Cancer Incidence in Singapore 2007-2011

Presence of national guidelines on gastric cancer: NO

Application of guidelines in clinical practice: YES

National Associations for research on gastric cancer: YES

Singapore Gastric Cancer Consortium

National Trials ongoing: YES

1. Gastric cancer epidemiology, clinical and genetic programme (**GCEP**) cohort study
2. Genomic-guided chemotherapy for advanced gastric cancer (**3G** study)
3. Randomized controlled trial comparing Rou-en-Y with Billroth II gastrojejunostomy after distal gastrectomy for cancer (**SCAR** Trial)
4. Extensive Peritoneal Lavage after Curative Gastrectomy for Gastric Cancer: a Randomized Controlled Trial (**EPL** Trial)

Relevant studies published in recent 2 years: *selected only impact factor >10*

- Zang ZJ et al: *Exome Sequencing of Gastric Adenocarcinoma Reveals Recurrent Somatic Mutations in Cell Adhesion and Chromatin Remodeling Genes. Nature Genetics 2012; 44(5):570-4. IF = 36.377*
- Kamikubo Y et al. Accelerated leukemogenesis by truncated CBF β -SMMHC defective in high-affinity binding with RUNX1. *Cancer Cell 2010;17(5):455-68. IF = 26.925*
- Palanisamy N et al: Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. *Nature Medicine 2010;16(7):793-8. IF = 25.4*
- Tan IB et al: Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. *Gastroenterology 2011;;141(2):476-485.e11.. IF = 12.403*
- Ito K et al: Loss of Runx3 is a key event in inducing precancerous state of the stomach. *Gastroenterology 2011;140(5):1536-1546. IF = 12.403*





Spain

Incidence:
Males: 16.4/100.000 Females: 7.5/100.000
Mortality:
Males: 10.8 /100.000 Females: 4.8/100.000
Presence of national guidelines on gastric cancer: N.A.
National Associations for research on gastric cancer: N.A.
National Trials ongoing: YES
54 studies found for gastric cancer on www.clinicaltrials.gov
Relevant studies published in recent 2 years:
Intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma: topography of locoregional recurrences and long-term outcomes. Calvo FA, Sole CV, Obregón R, Gómez-Espí M, González-San Segundo C, González-Bayón L, Alvarez E, García-Sabrido JL. Clin Transl Oncol. 2013 Jun;15(6):443-9
A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. Gómez-Martín C, Salazar R, Montagut C, Gil-Martín M, Núñez JA, Puig M, Lin X, Khosravan R, Tursi JM, Lechuga MJ, Bellmunt J Invest New Drugs. 2013 Apr;31(2):390-8.
Metastatic lymph node ratio versus number of metastatic lymph nodes as a prognostic factor in gastric cancer. Espín F, Bianchi A, Llorca S, Feliu J, Palomera E, García O, Remon J, Suñol X. Eur J Surg Oncol. 2012 Jun;38(6):497-502
Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project. González CA, Megraud F, T, Carneiro F, Fenge C, Riboli E. Ann Oncol. 2012 May;23(5):1320-4
HER-2 Evaluation in a Specific Gastric Cancer Population with the Highest Rate of Mortality in Spain. Cidon EU, Centeno RG, Lagarto EG, Peral JI. J Oncol. 2011;2011:391564



SWEDEN

Authors:

Peter Gunvén

Incidence:
Males: 12/100.000 Females: 7/100.000 All: 5,8/100.000
Mortality:
relative 5 year survival 23 %
Presence of national guidelines on gastric cancer: YES
But inadequate surgical guidelines
Application of guidelines in clinical practice: VARYING
National Associations for research on gastric cancer: NONE
National Trials ongoing: NONE limited to gastric cancer
Relevant studies published in recent 2 years: NONE



SWITZERLAND

Authors:

P.M. SCHNEIDER, M. SCHIESSER
University Hospital Zurich and KS St. Gallen


Incidence:

Males: 10.4/100.000 Females: 5/100.000

Mortality:

Males: 6.5/100.000 Females: 3,2/100.000

Stomach cancer, 2005–2009



¹ Incidence estimate based on cancer-registry data (see data and methods)

Source: FSO: COD, NICER, CCR

© FSO

Presence of national guidelines on gastric cancer: NO

Application of guidelines in clinical practice: NO

German S3 Guidelines in some institutions

National Associations for research on gastric cancer:

Swiss Association for Clinical Cancer Research (SAKK)

National Trials ongoing: YES (*Esophageal and Esophagogastric Junction Tumors*)

SAKK 75/08 Multimodal therapy with and without cetuximab in patients with locally advanced esophageal and esophagogastric junction cancers: an open-label phase III trial (accrual almost completed)

Relevant studies published in recent 2 years: 5 (*esophagogastric junction included*)

Ruhstaller T, Pless M, Dietrich D, Kranzbuehler H, von Moos R, Moosmann P, Montemurro M, Schneider PM, Rauch D, Gautschi O, Mingrone W, Widmer L, Inauen R, Brauchli P, Hess V.

Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06).

J Clin Oncol. 2011 Feb 20;29(6):626-31.



THAILAND

Authors:

P. Tomtitchong

Incidence:

All: 5/100.000

Mortality:

1-year and 5-year survival rates were 47% and 0%.

Presence of national guidelines on gastric cancer: On Going Process

Application of guidelines in clinical practice: YES

Asia–Pacific consensus guidelines on gastric cancer prevention
Journal of Gastroenterology and Hepatology **23 (2008) 351–365**

National Associations for research on gastric cancer: YES

National Gastric Cancer and *Helicobacter pylori* Research Center of Thailand

National Trials ongoing: YES

Thailand Gastric cancer community survey (Ongoing research)

Relevant studies published in recent 2 years:

- Mahachai V et al: Sequential Therapy in Clarithromycin Sensitive and Resistant *H. pylori* Based on PCR Molecular Test. *J Gastroenterol Hepatol* 2011; 26(5):825-8.
- Vilaichone et al: *CagA* genotype and Metronidazole resistant strain of *Helicobacter pylori* in Functional dyspepsia in Thailand. *J Gastroenterol Hepatol* 2011 ;26 Suppl 3:46-8.
- Mahachai V et al: Current Status of *Helicobacter pylori* Infection in Thailand. *Helicobacter Research* 2011; 15(3):
- Miwa H et al: Asian Consensus Report on Functional Dyspepsia. *J Gastroenterol Hepatol* 2011 Dec 6
- Tomtitchong P, *Systematic Review and Meta-Analysis: Helicobacter pylori Eradication Therapy After Simple Closure of Perforated Duodenal Ulcer*. *Helicobacter* 2012;17(2):148-152.
- Kongchayanun C, et al: Pilot studies to identify the optimum duration of concomitant *Helicobacter pylori* eradication therapy in Thailand. *Helicobacter* 2012;17(4):282-5.
- Sahara S et al : *Role of Helicobacter pylori cagA EPIYA motif and vacA genotypes for the development of gastrointestinal diseases in Southeast Asian countries: a meta-analysis*. *BMC Infect Dis*. *BMC Infect Dis* 012;12(1)
- Prasertpetmanee S et al: *Improved efficacy of PPI – amoxicillin - clarithromycin triple therapy for H. pylori eradication in low clarithromycin resistance areas or for tailored therapy*. *Helicobacter*. 2013 Jan 29.
- Vilaichone RK et al: Extremely high prevalence of *Helicobacter pylori* infection in Bhutan. *World Journal Gastroenterol* 2013 ;19(18):2806-10.
- Vilaichone RK et al: The antibiotics resistant rate of *Helicobacter pylori* in Bhutan. *World J Gastroenterol* (in press)



TURKEY

Authors:

Cambay Emel

Incidence:
Males: 8.21/100.000 Females: 6.99/
Mortality:
Males: 8.9/100.000 Females: 4.5/100.000
Presence of national guidelines on gastric cancer: NO
Application of guidelines in clinical practice: YES
National Associations for research on gastric cancer: NO
National Trials ongoing: NO
Relevant studies published in recent 2 years:



UKRAINE

Authors:

prof. I.B.Shchepotin, A.V. Lukashenko, O.O. Kolesnik, D.O. Rozumiy, Y.O.Zhukov, A.A. Burlaka

Incidence:

Males: 32/100.000

Females: 18.4/100.000

Both sex: 24.7/100.000

New Cases in 2012: 11252

Stage distribution of new cases, 2012 (according to TNM)

Stages I-II	36.3%
Stages III	24.6%
Stages IV	32.7%
Not specified	5.6%

Mortality:

Males: 24.2/100.000 Females: 13.5/100.000 Both Sex: 18.4/100.000

New Cases in 2012: 8518

Presence of national guidelines on gastric cancer: YES

Application of guidelines in clinical practice: YES

National Associations for research on gastric cancer: NO

National Trials ongoing: YES

Multivisceral resections for T4 gastric cancer tumors.

Gastrectomy with bursectomy versus standard gastrectomy for gastric cancer.

Efficacy of lymph node dissection for gastric cancer surgery.

Antireflux hand suturing technique for esophagogastrostomy after proximal gastrectomy.

Efficacy of neoadjuvant polichemotherapy within combined treatment gastric cancer patients

Relevant studies published in recent 2 years:

I.B. Shchepotin et al: *Neoadjuvant polychemotherapy in combined treatment of patients with gastric cancer* . Modern methods for diagnosis and treatment of patients with malignancies

Clin. Oncology. - 2012. - № 6 (2). - P. 146

I.B. Shchepotin et al: *Surgical treatment of patients with locally advanced gastric cancers (T 4)*.

Modern methods for diagnosis and treatment of patients with malignancies

Clin. Oncology. - 2012. - № 6 (2). - P. 145-146

I.B. Shchepotin et al: *Neoadjuvant polichemotherapy within combined treatment gastric cancer patients: rationale use and evaluation of effectiveness*. Modern methods for diagnosis and treatment of patients with malignancies: : Clin. Oncology. - 2012. - № 6 (2). - P. 26-30



HUNGARY

Authors: *Dezső Tóth M.D., Ph.D.¹, Lajos Orbán M.D.²*

¹*Dept. of General Surgery, Kenézy Teaching Hospital, Debrecen*

²*Dept. of Surgery, Medical Faculty of Pécs University, Pécs*

Incidence:
Males: 20,3/100.000 Females: 9,7/100.000
Mortality:
Males: 16,1/100.000 Females: 7,5/100.000 Both sexes: 14/100.000
Presence of national guidelines on gastric cancer: YES
Application of guidelines in clinical practice: YES
National Associations for research on gastric cancer: NO
National Trials ongoing: YES
<ul style="list-style-type: none">- Measuring the levels of fasting and postalimentary plasma cholecystokinin, ghrelin and leptin in two different reconstruction types (with or without the preservation of the duodenal passage) and comparing to healthy controls.- Measuring the levels of ghrelin and leptin, evaluation of the food intake and body weight gain in two different reconstruction types (with or without the preservation of the duodenal passage) in a rat animal model.- Effects of anti-cholecystokinin for food intake in two different reconstruction groups (with or without the preservation of the duodenal passage) in animal model.- Prognostic value of Maruyama Index in overall survival and disease free survival.- Accuracy of Maruyama computer program in patients with metastatic sentinel lymph node.
Relevant studies published in recent 2 years
<ul style="list-style-type: none">- Szabó M: <i>Postgastrectomy symptoms following total gastrectomy with or without preservation of the duodenal passage.</i> Magy Seb. 2011;64:277-82.- Tóth D: <i>Value of sentinel lymph node mapping using a blue dye-only method in gastric cancer: a single-center experience from North-East Hungary.</i> Gastric Cancer 2011;14:360-4.- Tóth D: <i>Prospective, comparative study for the evaluation of lymph node involvement in gastric cancer: Maruyama computer program versus sentinel lymph node biopsy.</i> Gastric Cancer. 2013; 16:201-7



URUGUAY

Authors:

L.Borgno

Incidence:

Males: 14.36/100.000 Females: 6.4/100.000

Mortality:

Males: 11.37/100.000 Females: 4.79/100.000

Presence of national guidelines on gastric cancer: NO

Application of guidelines in clinical practice: NO

National Associations for research on gastric cancer: NO

National Trials ongoing: NO


Relevant studies published in recent 2 years:

Viola Malet M; Pino AL; Muniz N. Pereyra L; Rodríguez P; Laurini M; Sánchez G. Cirugía laparoscópica del cáncer gástrico (Laparoscopic surgery of gastric cancer). En: 63º Congreso Uruguayo de Cirugía. 21-24 nov. 2012 .

Viola Malet M; Pino AL; Rodríguez P; ; Sánchez G.Laurini M; Castelli F. Linfadenectomía D2 laparoscópica en el cáncer gástrico localmente avanzado. (Laparoscopic D2 Lymphadenectomy in locally advanced gastric cancer) En: 63º Congreso Uruguayo de Cirugía. 21-24 nov. 2012. .

Zeoli M; Tarigo N; Lyford-Pike; Vásquez L;. GIST gástrico en paciente de 85 años. (Gastric GIST in 85 years old patient)En: 63º Congreso Uruguayo de Cirugía. 21-24 nov. 2012..


Borgno L; Secondo G; Rodríguez JL; Chinelli J: Cancer del muñón gástrico. (Stump gastric cancer) Sociedad de Cirugía del Uruguay June 2011




USA

Authors:

Paul Mansfield
MD Anderson Cancer Center, Houston, TX.
Arrington AK, Luu C, Falor A, Ko M, Lee B, Lin J, Park J, Kim J;
City of Hope Comprehensive Cancer Center, Duarte

Incidence:	
Males: 13.2/100.000 Females: 8.3/100.000	
Mortality:	
2013: Males: 2013: 6,740 deaths Females: 4.250 deaths	
Presence of national guidelines on gastric cancer: YES	
<i>NCCN guidelines</i> www.nccn.org	
<i>American Joint Committee on Cancer (7th Edition)</i>	
Application of guidelines in clinical practice: YES	
<i>High center/physician variation</i>	
National Associations for research on gastric cancer: <i>None specific for it. However, cooperative groups do coordinate these</i> National Comprehensive Cancer Network, American Cancer Society	
National Trials ongoing: YES	
<ul style="list-style-type: none"> - RTOG 1010: Phase III trial of preop chemoRT +/- Herceptin for HER2 positive esophageal/ GEJ cab. - TROG 0808: Phase II/III trial of <i>preop chemoRT vs preop chemo</i> (Canadian study but open to US centers) - Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial - HELIOSE Study: A Study of Herceptin (Trastuzumab in Combination With Cisplatin/Capecitabine Chemotherapy in Patients with HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer - A Study of Trastuzumab Emtansine Versus Taxane in Patients with Advance Gastric Cancer - Everolimus and Combination Chemotherapy in Treating Patients with Metastatic Stomach or Esophageal Cancer - Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma 	
Numerous other studies available on: www.clinicaltrials.gov http://www.cancer.gov/clinicaltrials	
Relevant studies published in recent 2 years:	

Other Countries present at 10th IGCC And participants




Albania	2
Algeria	1
Bahrain	1
Belgium	8
Bulgaria	5
Cameroon	1
Cape Verde	1
Christmas island	1
Colombia	1
Costa Rica	4
Croatia	1
Dominican Republic	1
Greece	5
Hungary	1
indonesia	5
iran	2
Iraq	3
irlanda	7
Jordan	5

Kenya	1
Malaysia	1
Mexico	3
Nigeria	2
Panama	1
Paraguay	1
Peru	5
Qatar	1
Romania	3
Saudi Arabia	1
Serbia	1
Sierra Leone	1
Slovakia	10
Slovenia	1
South Africa	1
United Arab Emirates	2
Uzbekistan	2
Bolivarian Republic of Venezuela	1

Overview of gastric cancer in the world

*Estimated Stomach Cancer Incidence
Worldwide in 2008*

▲ Estimated Stomach Cancer Incidence Worldwide in 2008: Men



Countries present at 10th IGCC, not represented in the poster session


* Eucan 2012: <http://eco.iarc.fr/EUCAN>

Albania*	36,2	Malaysia	10,70
Algeria	7,1	Mexico	9,40
Arab Emirates	5,60	Nigeria	3,20
Bahrain	8,1	Panama	14,3
Belgium*	12,20	Paraguay	13,90
Bulgaria*	21,40	Peru	22,60
Camerun	2,5	Portugal*	26,70
Cape Verde	7,8	Qatar	5,30
Colombia	23,40	Romania*	23,70
Costa Rica	28,50	Russian, Moscow	26,90
Croatia*	21,80	Saudi Arabia	4,5
Dominican Repub.	8,9	Serbia*	17,10
Greece*	11,10	Sierra Leone	5,40
Indonesia	9,40	Slovakia*	21,0
Iran	21,90	Slovenia*	23,30
Iraq	4,40	South Africa	4,50
Jordan	5,60	Spain*	16,40
Kazakistan	33,50	United Kingdom*	10,00
Kenya	9,20	Uzbekistan	16,90
Korea, republic of	62,20	Venezuela	13,3

Overview of gastric cancer in the world

*Estimated Stomach Cancer Incidence
Worldwide in 2008*

▲ **Estimated Stomach Cancer Incidence Worldwide in 2008: Women**



Countries present at 10th IGCC, not represented in the poster session


* Eucan 2012: <http://eco.iarc.fr/EUCAN>

Albania*	22.2	Malaysia	6.4
Algeria	4.4	Mexico	6.7
Arab Emirates	4.2	Nigeria	1.4
Bahrain	5.3	Panama	9.0
Belgium*	5.7	Paraguay	6.8
Bulgaria*	10.4	Peru	20
Camerun	1.6	Portugal*	12.8
Cape Verde	5.1	Qatar	4.8
Colombia	12.5	Romania*	8.5
Costa Rica	15.6	Russian, Moscow	11.7
Croatia*	7.4	Saudi Arabia	1.9
Dominican Repub.	7.4	Serbia*	8.1
Greece*	5.4	Sierra Leone	4.9
Indonesia	5.6	Slovakia*	9.8
Iran	9	Slovenia*	9.6
Iraq	3.2	South Africa	2.3
Jordan	4.1	Spain*	7.5
Kazakistan	12.4	United Kingdom*	4.8
Kenya	6.2	Uzbekistan	9.4
Korea, republic of	24.6	Venezuela	7.6

Overview of gastric cancer in the world

*Estimated Stomach Cancer Incidence
Worldwide in 2008*

▲ Estimated Stomach Cancer Mortality Worldwide in 2008: Men



Countries present at 10th IGCC, not represented in the poster session


* Eucan 2012: <http://eco.iarc.fr/EUCAN>

Albania*	31.0	Malaysia	9.5
Algeria	6.7	Mexico	7.9
Arab Emirates	4.8	Nigeria	3.1
Bahrain	6.3	Panama	12
Belgium*	7.8	Paraguay	11.9
Bulgaria*	17.9	Peru	19.5
Camerun	2.5	Portugal*	19.5
Cape Verde	7.8	Qatar	5.1
Colombia	17.8	Romania*	19.2
Costa Rica	23.6	Russian, Moscow	24
Croatia*	17.6	Saudi Arabia	4.2
Dominican Republic	6.8	Serbia*	14
Greece*	9.6	Sierra Leone	5.2
Indonesia	8.8	Slovakia*	14.6
Iran	19.9	Slovenia*	16.2
Iraq	4.3	South Africa	4.2
Jordan	5.2	Spain*	10.8
Kazakistan	28.3	United Kingdom*	6.6
Kenya	8.9	Uzbekistan	14.4
Korea, republic of	22.8	Venezuela	11.4

Overview of gastric cancer in the world

*Estimated Stomach Cancer Incidence
Worldwide in 2008*

▲ Estimated Stomach Cancer Mortality Worldwide in 2008: Women




Countries present at 10th IGCC, not represented in the poster session

* Eucan 2012: <http://eco.iarc.fr/EUCAN>

Albania*	18.8	Malaysia	5.6
Algeria	4.1	Mexico	5.8
Arab Emirates	3.5	Nigeria	1.3
Bahrain	2.5	Panama	8
Belgium*	3.5	Paraguay	5.9
Bulgaria*	8	Peru	17.1
Camerun	1.5	Portugal*	8.9
Cape Verde	5.1	Qatar	4.8
Colombia	9.6	Romania*	6.9
Costa Rica	10.6	Russian, Moscow	9.9
Croatia*	7.4	Saudi Arabia	1.7
Dominican Republic	5.6	Serbia*	6.3
Greece*	4.7	Sierra Leone	4.7
Indonesia	5.2	Slovakia*	6.9
Iran	8.2	Slovenia*	6.5
Iraq	3	South Africa	2.2
Jordan	3.8	Spain*	4.8
Kazakistan	11	United Kingdom*	3.1
Kenya	5.9	Uzbekistan	8.2
Korea, republic of	8.6	Venezuela	6.6

1268 studies found for GASTRIC CANCER

www.clinicaltrials.gov



Numbers of cilinical trials in the countries present at 10th IGCC not represented in the poster session

Albania*	-	Malaysia	5
Algeria	-	Mexico	18
Arab Emirates	-	Nigeria	1
Bahrain	-	Panama	5
Belgium*	45	Paraguay	-
Bulgaria*	9	Peru	9
Camerun	-	Portugal*	13
Cape Verde	-	Qatar	-
Colombia	7	Romania*	12
Costa Rica	2	Russian, Moscow	25
Croatia*	4	Saudi Arabia	-
Dominican Repub.	-	Serbia*	3
Greece*	8	Sierra Leone	0
Indonesia	2	Slovakia*	4
Iran	2	Slovenia*	1
Iraq	0	South Africa	9
Jordan	0	Spain*	53
Kazakistan	-	United Kingdom*	71
Kenya	0	Uzbekistan	-
Korea, republic of	201	Venezuela	-